• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.

作者信息

Croden Jennifer, Jen Wei-Ying, Marvin-Peek Jennifer, Xiao Lianchun, Bouligny Ian M, Loghavi Sanam, Borthakur Gautam, Daver Naval G, Abbas Hussein A, Takahashi Koichi, Sasaki Koji, Pemmaraju Naveen, Short Nicholas J, Hammond Danielle, Jabbour Elias, Masarova Lucia, Chien Kelly S, Issa Ghayas C, Montalban-Bravo Guillermo, Yilmaz Musa, Maiti Abhishek, Alvarado-Valero Yesid, Garcia-Manero Guillermo, Ravandi Farhad, Konopleva Marina Y, Kantarjian Hagop M, Kadia Tapan M, DiNardo Courtney D

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leukemia. 2025 Aug 14. doi: 10.1038/s41375-025-02733-0.

DOI:10.1038/s41375-025-02733-0
PMID:40813623
Abstract
摘要

相似文献

1
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.接受强化化疗和维奈托克治疗的新诊断异柠檬酸脱氢酶（IDH）突变型急性髓系白血病成年患者的治疗结果
Leukemia. 2025 Aug 14. doi: 10.1038/s41375-025-02733-0.
2
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.对于不符合强化化疗条件的异柠檬酸脱氢酶（IDH）突变型急性髓系白血病（AML）患者，采用去甲基化药物、维奈克拉和异柠檬酸脱氢酶抑制剂的一线三联方案的疗效。
J Clin Oncol. 2025 Aug 20;43(24):2692-2699. doi: 10.1200/JCO-25-00640. Epub 2025 Jun 13.
3
Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia.在新诊断的ASXL1突变型急性髓系白血病年轻成人患者中，维奈托克联合去甲基化药物比强化化疗有更好的反应和预后。
Cancer Med. 2025 Jul;14(14):e71037. doi: 10.1002/cam4.71037.
4
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.在英国国家医疗服务体系（NHS）中，使用维奈克拉和阿扎胞苷或小剂量阿糖胞苷治疗新诊断急性髓系白血病（AML）的真实世界疗效。
Blood Neoplasia. 2024 May 23;1(3):100017. doi: 10.1016/j.bneo.2024.100017. eCollection 2024 Sep.
5
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.文森特：一项随机对照试验，评估维奈克拉联合阿扎胞苷与强化化疗在新诊断的、NPM1突变型急性髓系白血病患者中的疗效。
Ann Hematol. 2025 Jul 9. doi: 10.1007/s00277-025-06496-7.
6
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed -Mutated or -Rearranged AML.阿扎胞苷、维奈克拉和瑞武尼布用于新诊断的伴有突变或重排的急性髓系白血病
J Clin Oncol. 2025 Aug 10;43(23):2606-2615. doi: 10.1200/JCO-25-00914. Epub 2025 Jun 12.
7
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.新诊断急性髓系白血病的八九十岁老人的当代治疗结果
Cancer. 2025 Aug 15;131(16):e70028. doi: 10.1002/cncr.70028.
8
Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.维奈托克单药或联合化疗用于复发/难治性急性髓系白血病的儿童和青少年/年轻成人患者
Pediatr Blood Cancer. 2025 Jul;72(7):e31714. doi: 10.1002/pbc.31714. Epub 2025 Apr 23.
9
Safety and Efficacy of Grapefruit Juice Combined With Low-Dose Venetoclax in AML Patients Ineligible for Intensive Chemotherapy.葡萄柚汁联合低剂量维奈克拉在不符合强化化疗条件的急性髓系白血病患者中的安全性和有效性
Clin Ther. 2025 Aug;47(8):595-601. doi: 10.1016/j.clinthera.2025.05.008. Epub 2025 Jun 13.
10
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.一项在门诊环境中进行的 Venetoclax 联合阿扎胞苷或地西他滨治疗急性髓系白血病患者的 3b 期研究。
Hematol Oncol. 2024 May;42(3):e3274. doi: 10.1002/hon.3274.

本文引用的文献

1
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.维奈托克联合FLAG-IDA诱导和巩固治疗新诊断、复发或难治性急性髓系白血病的长期结果
Leukemia. 2025 Apr;39(4):854-863. doi: 10.1038/s41375-025-02531-8. Epub 2025 Feb 25.
2
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.伴有 NPM1 突变的 IDH 突变型急性髓系白血病的当代预后：维奈托克治疗的影响。
Am J Hematol. 2022 Nov;97(11):1443-1452. doi: 10.1002/ajh.26694. Epub 2022 Sep 15.
3
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
维奈托克联合诱导化疗治疗新诊断的急性髓系白血病患者：一项事后、倾向评分匹配队列研究。
Lancet Haematol. 2022 May;9(5):e350-e360. doi: 10.1016/S2352-3026(22)00076-X.
4
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.依尼西尼（enasidenib）联合阿扎胞苷对比阿扎胞苷单药治疗新诊断、突变型 IDH2 急性髓系白血病患者（AG221-AML-005）：一项单臂、1b 期和随机、2 期试验。
Lancet Oncol. 2021 Nov;22(11):1597-1608. doi: 10.1016/S1470-2045(21)00494-0. Epub 2021 Oct 18.
5
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Venetoclax 联合克拉屈滨、伊达比星和阿糖胞苷强化化疗治疗初诊急性髓系白血病或高危骨髓增生异常综合征患者：来自单中心、单臂、2 期临床试验的一个队列研究。
Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.
6
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.突变型异柠檬酸脱氢酶 1 抑制剂伊维替尼联合阿扎胞苷治疗新诊断的急性髓系白血病。
J Clin Oncol. 2021 Jan 1;39(1):57-65. doi: 10.1200/JCO.20.01632. Epub 2020 Oct 29.
7
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.ivosidenib 或enasidenib 联合强化化疗治疗初诊 AML 患者的 1 期研究。
Blood. 2021 Apr 1;137(13):1792-1803. doi: 10.1182/blood.2020007233.
8
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.ivosidenib 治疗 IDH1 突变复发性或难治性 AML 的持久缓解。
N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
9
The role of IDH mutations in acute myeloid leukemia.IDH 突变在急性髓系白血病中的作用。
Future Oncol. 2018 Apr;14(10):979-993. doi: 10.2217/fon-2017-0523. Epub 2018 Mar 15.
10
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.靶向急性髓系白血病中的异柠檬酸脱氢酶1和异柠檬酸脱氢酶2突变
Curr Hematol Malig Rep. 2017 Dec;12(6):537-546. doi: 10.1007/s11899-017-0418-6.